pepdex
← Back to index
№ 065

Amycretin

Novo Nordisk's single-molecule GLP-1 + amylin co-agonist. Phase 1/2 in oral and subcutaneous formulations. The pharmacological consolidation of the Semaglutide + Cagrilintide concept into one peptide.

Fat Loss
Evidence: Moderate
Half-life
~5-7 days (sub-q form)
Route
Subcutaneous (sub-q form) or oral (oral form)
Cycle
Trial protocols
Schedule
Once weekly (sub-q) or once daily (oral)
In plain English

Amycretin is Novo Nordisk's experiment in putting Semaglutide and Cagrilintide together as one molecule instead of two separate drugs. Activates GLP-1 + amylin in a single injection. They're testing both an oral pill and a weekly injection. Phase 1/2 only — not available yet.

Status & legality
Natty?
Not natty
FDA
Not approved

Investigational. Phase 1/2 trials by Novo Nordisk in oral and subcutaneous formulations.

Compounding
Investigational

In clinical trials, not yet approved for prescription.

WADA
Not listed
Prescribed

Trial access only.

Who it's for

  • →Trial participants in obesity studies
  • →Followers of Novo's next-generation pipeline
  • →Educational reference for dual co-agonist design

What to expect

  1. Week 1

    Appetite drops. Some early-trial users reported faster onset than Semaglutide alone.

  2. Week 4

    First titration step.

  3. Week 8

    Phase 1b data showed weight loss outperforming Semaglutide-monotherapy comparators.

How it works (mechanism)

Single-molecule co-agonist — activates GLP-1 AND amylin receptors simultaneously. Pharmacological consolidation of the CagriSema concept into one peptide instead of two.

Dosing protocol

Trial doses still being established. Sub-q forms tested up to 20 mg weekly.

Stacks well with

Standalone — this IS the dual stack in one molecule

Side effects

01Nausea (less than Semaglutide monotherapy in early data)
02Reduced appetite
03Constipation

When NOT to use

  • ⚠MTC / MEN-2 history
  • ⚠Pancreatitis history
  • ⚠Pregnancy / nursing

Bloodwork to monitor

  • • Lipid panel
  • • A1C
  • • ALT/AST

Common mistakes

  • • Expecting trial-grade material from community vendors
  • • Treating it as available-now (Phase 1/2 still)
  • • Comparing oral form dosing to sub-q form dosing

Drug & supplement interactions

  • ⚠Combined GLP-1 + amylin warnings: insulin dose reduction; slowed oral absorption
  • ⚠Trial-only — full interaction profile not yet published

Educational only. User-specific dosing is between you and a qualified provider.

Frequently asked

What is Amycretin?+
Amycretin is Novo Nordisk's experiment in putting Semaglutide and Cagrilintide together as one molecule instead of two separate drugs. Activates GLP-1 + amylin in a single injection. They're testing both an oral pill and a weekly injection. Phase 1/2 only — not available yet.
Is Amycretin FDA approved?+
Investigational. Phase 1/2 trials by Novo Nordisk in oral and subcutaneous formulations.
Is Amycretin banned by WADA?+
Amycretin is not currently on the WADA prohibited list.
Are you still natty after taking Amycretin?+
No. Amycretin is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe Amycretin?+
Trial access only.
What's the typical dose of Amycretin?+
Trial doses still being established. Sub-q forms tested up to 20 mg weekly.
What are the side effects of Amycretin?+
Common side effects include: Nausea (less than Semaglutide monotherapy in early data); Reduced appetite; Constipation. Less common effects and full safety details are on the entry page.
How long until Amycretin starts working?+
Appetite drops. Some early-trial users reported faster onset than Semaglutide alone.

More in Fat Loss

№ 008
Tirzepatide

Dual agonist (GLP-1 + GIP). FDA-approved as Mounjaro / Zepbound. Strong weight loss with cleaner side effect profile than semaglutide.

№ 009
Semaglutide

GLP-1 agonist. The original wave. Sold as Ozempic / Wegovy.

№ 003
Retatrutide

Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.

№ 058
Liraglutide (Saxenda / Victoza)

Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.